Drug Trial Radar · NCT05099822
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-97489 in Healthy Adult Participants
Last checked: Nov 19, 2026Latest source record: Dec 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
84
Actual
Start
Mar 13, 2020
Primary completion
Jul 11, 2022
Study completion Jul 11, 2022
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Oct 29, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study aims to evaluate the safety, tolerability, of CC-97489
Conditions
- Healthy Volunteers
Interventions
CC-97489Drug
Specified dose on specified days
PlaceboOther
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events (AEs)Time frame: 28 days after the last dose
- Incidence of Serious Adverse Events (SAEs)Time frame: 28 days after the last dose
- Number of participants with clinically significant changes in electrocardiogram parametersTime frame: Day 21
- Incidence of clinically significant changes in vital signs: Body temperatureTime frame: Day 21
- Incidence of clinically significant changes in vital signs: Respiratory rateTime frame: Day 21
- Incidence of clinically significant changes in vital signs: Blood pressureTime frame: Day 21
- Incidence of clinically significant changes in vital signs: Heart rateTime frame: Day 21
- Incidence of clinically significant changes in clinical laboratory results: Hematology testsTime frame: Day 18
- Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry testsTime frame: Day 18
- Incidence of clinically significant changes in clinical laboratory results: Urinalysis testsTime frame: Day 18
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Local Institution - 001
Leuven, Vlaams Brabant, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.